- Tytuł:
- Interplay between inflammation and thrombosis in cardiovascular pathology.
- Autorzy:
- Źródło:
- Nature reviews. Cardiology [Nat Rev Cardiol] 2021 Sep; Vol. 18 (9), pp. 666-682. Date of Electronic Publication: 2021 May 06.
- Typ publikacji:
- Journal Article; Review
- Język:
- English
- Imprint Name(s):
- Original Publication: London : Nature Pub. Group
- MeSH Terms:
-
Anti-Inflammatory Agents/*therapeutic use
Blood Coagulation/*drug effects
Fibrinolytic Agents/*therapeutic use
Immune System/*drug effects
Inflammation/*drug therapy
Inflammation Mediators/*antagonists & inhibitors
Thrombosis/*prevention & control
Anti-Inflammatory Agents/adverse effects ; COVID-19/blood ; COVID-19/immunology ; Fibrinolytic Agents/adverse effects ; Humans ; Immune System/immunology ; Immune System/metabolism ; Inflammation/blood ; Inflammation/immunology ; Inflammation Mediators/metabolism ; Risk Assessment ; Risk Factors ; Signal Transduction ; Thrombosis/blood ; Thrombosis/immunology - References:
-
Engelmann, B. & Massberg, S. Thrombosis as an intravascular effector of innate immunity. Nat. Rev. Immunol. 13, 34–45 (2013). (PMID: 2322250210.1038/nri3345)
Ackermann, M. et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. N. Engl. J. Med. 383, 120–128 (2020). (PMID: 32437596741275010.1056/NEJMoa2015432)
Nicolai, L. et al. Immunothrombotic dysregulation in COVID-19 pneumonia is associated with respiratory failure and coagulopathy. Circulation 142, 1176–1189 (2020). (PMID: 32755393749789210.1161/CIRCULATIONAHA.120.048488)
Wichmann, D. et al. Autopsy findings and venous thromboembolism in patients with COVID-19: a prospective cohort study. Ann. Intern. Med. 173, 268–277 (2020). (PMID: 3237481510.7326/M20-2003)
Creel-Bulos, C. et al. Acute cor pulmonale in critically ill patients with Covid-19. N. Engl. J. Med. 382, e70 (2020). (PMID: 3237495610.1056/NEJMc2010459)
Cui, S., Chen, S., Li, X., Liu, S. & Wang, F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J. Thromb. Haemost. 18, 1421–1424 (2020). (PMID: 3227198810.1111/jth.14830)
Klok, F. A. et al. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis. Thromb. Res. 191, 148–150 (2020). (PMID: 32381264719210110.1016/j.thromres.2020.04.041)
Klok, F. A. et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb. Res. 191, 145–147 (2020). (PMID: 32291094714671410.1016/j.thromres.2020.04.013)
Poissy, J. et al. Pulmonary embolism in COVID-19 patients: awareness of an increased prevalence. Circulation 142, 184–186 (2020). (PMID: 3233008310.1161/CIRCULATIONAHA.120.047430)
Oxley, T. J. et al. Large-vessel stroke as a presenting feature of Covid-19 in the young. N. Engl. J. Med. 382, e60 (2020). (PMID: 3234350410.1056/NEJMc2009787)
Bangalore, S. et al. ST-segment elevation in patients with Covid-19 – a case series. N. Engl. J. Med. 382, 2478–2480 (2020). (PMID: 3230208110.1056/NEJMc2009020)
Stefanini, G. G. et al. ST-elevation myocardial infarction in patients with COVID-19: clinical and angiographic outcomes. Circulation 141, 2113–2116 (2020). (PMID: 32352306730206210.1161/CIRCULATIONAHA.120.047525)
Jackson, S. P. Arterial thrombosis–insidious, unpredictable and deadly. Nat. Med. 17, 1423–1436 (2011). (PMID: 2206443210.1038/nm.2515)
Mackman, N. Triggers, targets and treatments for thrombosis. Nature 451, 914–918 (2008). (PMID: 18288180284850910.1038/nature06797)
Mackman, N. New insights into the mechanisms of venous thrombosis. J. Clin. Invest. 122, 2331–2336 (2012). (PMID: 22751108338681110.1172/JCI60229)
Hottz, E. D. et al. Platelets mediate increased endothelium permeability in dengue through NLRP3-inflammasome activation. Blood 122, 3405–3414 (2013). (PMID: 24009231382911410.1182/blood-2013-05-504449)
Semple, J. W., Italiano, J. E. Jr. & Freedman, J. Platelets and the immune continuum. Nat. Rev. Immunol. 11, 264–274 (2011). (PMID: 2143683710.1038/nri2956)
Gaertner, F. et al. Migrating platelets are mechano-scavengers that collect and bundle bacteria. Cell 171, 1368–1382 (2017). (PMID: 2919507610.1016/j.cell.2017.11.001)
Nicolai, L. et al. Vascular surveillance by haptotactic blood platelets in inflammation and infection. Nat. Commun. 11, 5778 (2020). (PMID: 33188196766658210.1038/s41467-020-19515-0)
Brinkmann, V. et al. Neutrophil extracellular traps kill bacteria. Science 303, 1532–1535 (2004). (PMID: 10.1126/science.109238515001782)
Fuchs, T. A. et al. Extracellular DNA traps promote thrombosis. Proc. Natl Acad. Sci. USA 107, 15880–15885 (2010). (PMID: 20798043293660410.1073/pnas.1005743107)
von Bruhl, M. L. et al. Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo. J. Exp. Med. 209, 819–835 (2012). (PMID: 10.1084/jem.20112322)
Xu, J. et al. Extracellular histones are major mediators of death in sepsis. Nat. Med. 15, 1318–1321 (2009). (PMID: 19855397278375410.1038/nm.2053)
Kenny, E. F. et al. Diverse stimuli engage different neutrophil extracellular trap pathways. eLife 6, e24437 (2017). (PMID: 28574339549673810.7554/eLife.24437)
Lewis, H. D. et al. Inhibition of PAD4 activity is sufficient to disrupt mouse and human NET formation. Nat. Chem. Biol. 11, 189–191 (2015). (PMID: 25622091439758110.1038/nchembio.1735)
Martinod, K. et al. Neutrophil histone modification by peptidylarginine deiminase 4 is critical for deep vein thrombosis in mice. Proc. Natl Acad. Sci. USA 110, 8674–8679 (2013). (PMID: 23650392366675510.1073/pnas.1301059110)
Li, P. et al. PAD4 is essential for antibacterial innate immunity mediated by neutrophil extracellular traps. J. Exp. Med. 207, 1853–1862 (2010). (PMID: 20733033293116910.1084/jem.20100239)
Sollberger, G., Tilley, D. O. & Zychlinsky, A. Neutrophil extracellular traps: the biology of chromatin externalization. Dev. Cell 44, 542–553 (2018). (PMID: 2953377010.1016/j.devcel.2018.01.019)
Silvestre-Roig, C., Hidalgo, A. & Soehnlein, O. Neutrophil heterogeneity: implications for homeostasis and pathogenesis. Blood 127, 2173–2181 (2016). (PMID: 2700211610.1182/blood-2016-01-688887)
Uhl, B. et al. Aged neutrophils contribute to the first line of defense in the acute inflammatory response. Blood 128, 2327–2337 (2016). (PMID: 27609642512231010.1182/blood-2016-05-718999)
Zhang, D. et al. Neutrophil ageing is regulated by the microbiome. Nature 525, 528–532 (2015). (PMID: 26374999471263110.1038/nature15367)
Jimenez-Alcazar, M. et al. Host DNases prevent vascular occlusion by neutrophil extracellular traps. Science 358, 1202–1206 (2017). (PMID: 2919191010.1126/science.aam8897)
Hakkim, A. et al. Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis. Proc. Natl Acad. Sci. USA 107, 9813–9818 (2010). (PMID: 20439745290683010.1073/pnas.0909927107)
Sreeramkumar, V. et al. Neutrophils scan for activated platelets to initiate inflammation. Science 346, 1234–1238 (2014). (PMID: 25477463428084710.1126/science.1256478)
Clark, S. R. et al. Platelet TLR4 activates neutrophil extracellular traps to ensnare bacteria in septic blood. Nat. Med. 13, 463–469 (2007). (PMID: 1738464810.1038/nm1565)
Rossaint, J. et al. Directed transport of neutrophil-derived extracellular vesicles enables platelet-mediated innate immune response. Nat. Commun. 7, 13464 (2016). (PMID: 27845343511607210.1038/ncomms13464)
Verschoor, A. & Langer, H. F. Crosstalk between platelets and the complement system in immune protection and disease. Thromb. Haemost. 110, 910–919 (2013). (PMID: 2400892710.1160/TH13-02-0102)
Schmidt, C. Q. & Verschoor, A. Complement and coagulation: so close, yet so far. Blood 130, 2581–2582 (2017). (PMID: 2924220710.1182/blood-2017-10-811943)
Peerschke, E. I., Yin, W. & Ghebrehiwet, B. Complement activation on platelets: implications for vascular inflammation and thrombosis. Mol. Immunol. 47, 2170–2175 (2010). (PMID: 20621693290432610.1016/j.molimm.2010.05.009)
Polley, M. J. & Nachman, R. The human complement system in thrombin-mediated platelet function. J. Exp. Med. 147, 1713–1726 (1978). (PMID: 68187910.1084/jem.147.6.1713)
Verschoor, A. et al. A platelet-mediated system for shuttling blood-borne bacteria to CD8α dendritic cells depends on glycoprotein GPIb and complement C3. Nat. Immunol. 12, 1194–1201 (2011). (PMID: 2203760210.1038/ni.2140)
Massberg, S. et al. Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases. Nat. Med. 16, 887–896 (2010). (PMID: 2067610710.1038/nm.2184)
Yipp, B. G. et al. Infection-induced NETosis is a dynamic process involving neutrophil multitasking in vivo. Nat. Med. 18, 1386–1393 (2012). (PMID: 22922410452913110.1038/nm.2847)
Wu, C. et al. Inflammasome activation triggers blood clotting and host death through pyroptosis. Immunity 50, 1401–1411 (2019). (PMID: 31076358679153110.1016/j.immuni.2019.04.003)
Bach, R., Gentry, R. & Nemerson, Y. Factor VII binding to tissue factor in reconstituted phospholipid vesicles: induction of cooperativity by phosphatidylserine. Biochemistry 25, 4007–4020 (1986). (PMID: 352726110.1021/bi00362a005)
Yang, X. et al. Bacterial endotoxin activates the coagulation cascade through gasdermin D-dependent phosphatidylserine exposure. Immunity 51, 983–996 (2019). (PMID: 3183642910.1016/j.immuni.2019.11.005)
Reinhardt, C. et al. Protein disulfide isomerase acts as an injury response signal that enhances fibrin generation via tissue factor activation. J. Clin. Invest. 118, 1110–1122 (2008). (PMID: 182746742242616)
Burzynski, L. C. et al. The coagulation and immune systems are directly linked through the activation of interleukin-1α by thrombin. Immunity 50, 1033–1042 (2019). (PMID: 30926232647640410.1016/j.immuni.2019.03.003)
Pietras, E. M. Inflammation: a key regulator of hematopoietic stem cell fate in health and disease. Blood 130, 1693–1698 (2017). (PMID: 28874349563948510.1182/blood-2017-06-780882)
Haas, S. et al. Inflammation-induced emergency megakaryopoiesis driven by hematopoietic stem cell-like megakaryocyte progenitors. Cell Stem Cell 17, 422–434 (2015). (PMID: 2629957310.1016/j.stem.2015.07.007)
Schönrich, G. & Raftery, M. J. Neutrophil extracellular traps go viral. Front. Immunol. 7, 366 (2016). (PMID: 27698656502720510.3389/fimmu.2016.00366)
Jenne, C. N. et al. Neutrophils recruited to sites of infection protect from virus challenge by releasing neutrophil extracellular traps. Cell Host Microbe 13, 169–180 (2013). (PMID: 2341475710.1016/j.chom.2013.01.005)
Boilard, E. et al. Influenza virus H1N1 activates platelets through FcγRIIA signaling and thrombin generation. Blood 123, 2854–2863 (2014). (PMID: 2466513610.1182/blood-2013-07-515536)
Koupenova, M. et al. The role of platelets in mediating a response to human influenza infection. Nat. Commun. 10, 1780 (2019). (PMID: 30992428646790510.1038/s41467-019-09607-x)
Funchal, G. A. et al. Respiratory syncytial virus fusion protein promotes TLR-4-dependent neutrophil extracellular trap formation by human neutrophils. PLoS ONE 10, e0124082 (2015). (PMID: 25856628439175010.1371/journal.pone.0124082)
Tripathi, S., Verma, A., Kim, E. J., White, M. R. & Hartshorn, K. L. LL-37 modulates human neutrophil responses to influenza A virus. J. Leukoc. Biol. 96, 931–938 (2014). (PMID: 25082153419756310.1189/jlb.4A1113-604RR)
Narasaraju, T. et al. Excessive neutrophils and neutrophil extracellular traps contribute to acute lung injury of influenza pneumonitis. Am. J. Pathol. 179, 199–210 (2011). (PMID: 21703402312387310.1016/j.ajpath.2011.03.013)
Nicolai, L. et al. Vascular neutrophilic inflammation and immunothrombosis distinguish severe COVID-19 from influenza pneumonia. J. Thromb. Haemost. 19, 574–581 (2020). (PMID: 3321713410.1111/jth.15179)
Doss, M. et al. Interactions of α-, β-, and θ-defensins with influenza A virus and surfactant protein D. J. Immunol. 182, 7878–7887 (2009). (PMID: 1949431210.4049/jimmunol.0804049)
Hartshorn, K. L., White, M. R., Tecle, T., Holmskov, U. & Crouch, E. C. Innate defense against influenza A virus: activity of human neutrophil defensins and interactions of defensins with surfactant protein D. J. Immunol. 176, 6962–6972 (2006). (PMID: 1670985710.4049/jimmunol.176.11.6962)
Salvatore, M. et al. α-Defensin inhibits influenza virus replication by cell-mediated mechanism(s). J. Infect. Dis. 196, 835–843 (2007). (PMID: 1770341310.1086/521027)
Barlow, P. G. et al. Antiviral activity and increased host defense against influenza infection elicited by the human cathelicidin LL-37. PLoS ONE 6, e25333 (2011). (PMID: 22031815319873410.1371/journal.pone.0025333)
Meier, C. R., Jick, S. S., Derby, L. E., Vasilakis, C. & Jick, H. Acute respiratory-tract infections and risk of first-time acute myocardial infarction. Lancet 351, 1467–1471 (1998). (PMID: 960580210.1016/S0140-6736(97)11084-4)
Smeeth, L. et al. Risk of myocardial infarction and stroke after acute infection or vaccination. N. Engl. J. Med. 351, 2611–2618 (2004). (PMID: 1560202110.1056/NEJMoa041747)
Corrales-Medina, V. F. et al. Cardiac complications in patients with community-acquired pneumonia: incidence, timing, risk factors, and association with short-term mortality. Circulation 125, 773–781 (2012). (PMID: 2221934910.1161/CIRCULATIONAHA.111.040766)
Dalager-Pedersen, M., Sogaard, M., Schonheyder, H. C., Nielsen, H. & Thomsen, R. W. Risk for myocardial infarction and stroke after community-acquired bacteremia: a 20-year population-based cohort study. Circulation 129, 1387–1396 (2014). (PMID: 2452343310.1161/CIRCULATIONAHA.113.006699)
Beristain-Covarrubias, N. et al. Understanding infection-induced thrombosis: lessons learned from animal models. Front. Immunol. 10, 2569 (2019). (PMID: 31749809684806210.3389/fimmu.2019.02569)
Grayston, J. T. et al. Azithromycin for the secondary prevention of coronary events. N. Engl. J. Med. 352, 1637–1645 (2005). (PMID: 1584366610.1056/NEJMoa043526)
O’Connor, C. M. et al. Azithromycin for the secondary prevention of coronary heart disease events: the WIZARD study: a randomized controlled trial. JAMA 290, 1459–1466 (2003). (PMID: 1312998510.1001/jama.290.11.1459)
McDonald, B. et al. Platelets and neutrophil extracellular traps collaborate to promote intravascular coagulation during sepsis in mice. Blood 129, 1357–1367 (2017). (PMID: 28073784534573510.1182/blood-2016-09-741298)
Schumski, A. et al. Endotoxinemia accelerates atherosclerosis via electrostatic charge-mediated monocyte adhesion. Circulation 143, 254–266 (2020). (PMID: 3316768410.1161/CIRCULATIONAHA.120.0466777914394)
Ammollo, C. T., Semeraro, F., Xu, J., Esmon, N. L. & Esmon, C. T. Extracellular histones increase plasma thrombin generation by impairing thrombomodulin-dependent protein C activation. J. Thromb. Haemost. 9, 1795–1803 (2011). (PMID: 2171144410.1111/j.1538-7836.2011.04422.x)
Semeraro, F., Ammollo, C. T., Esmon, N. L. & Esmon, C. T. Histones induce phosphatidylserine exposure and a procoagulant phenotype in human red blood cells. J. Thromb. Haemost. 12, 1697–1702 (2014). (PMID: 25069624419415410.1111/jth.12677)
Semeraro, F. et al. Extracellular histones promote thrombin generation through platelet-dependent mechanisms: involvement of platelet TLR2 and TLR4. Blood 118, 1952–1961 (2011). (PMID: 21673343315872210.1182/blood-2011-03-343061)
Landsem, A. et al. The key roles of complement and tissue factor in Escherichia coli-induced coagulation in human whole blood. Clin. Exp. Immunol. 182, 81–89 (2015). (PMID: 26241501457851110.1111/cei.12663)
Ovstebo, R. et al. Microparticle-associated tissue factor activity is reduced by inhibition of the complement protein 5 in Neisseria meningitidis-exposed whole blood. Innate Immun. 20, 552–560 (2014). (PMID: 2405110210.1177/1753425913502099)
Norgaard, I., Nielsen, S. F. & Nordestgaard, B. G. Complement C3 and high risk of venous thromboembolism: 80517 individuals from the Copenhagen general population study. Clin. Chem. 62, 525–534 (2016). (PMID: 2679768610.1373/clinchem.2015.251314)
Goshua, G. et al. Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study. Lancet Haematol. 7, e575–e582 (2020). (PMID: 32619411732644610.1016/S2352-3026(20)30216-7)
Zhang, Y. et al. Coagulopathy and antiphospholipid antibodies in patients with Covid-19. N. Engl. J. Med. 382, e38 (2020). (PMID: 3226802210.1056/NEJMc2007575)
Zhou, F. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395, 1054–1062 (2020). (PMID: 32171076727062710.1016/S0140-6736(20)30566-3)
Tang, N., Li, D., Wang, X. & Sun, Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J. Thromb. Haemost. 18, 844–847 (2020). (PMID: 32073213716650910.1111/jth.14768)
Chen, G. et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J. Clin. Invest. 130, 2620–2629 (2020). (PMID: 32217835719099010.1172/JCI137244)
Hamming, I. et al. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J. Pathol. 203, 631–637 (2004). (PMID: 15141377716772010.1002/path.1570)
Varga, Z. et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet 395, 1417–1418 (2020). (PMID: 32325026717272210.1016/S0140-6736(20)30937-5)
Mancini, I. et al. The ADAMTS13-von Willebrand factor axis in COVID-19 patients. J. Thromb. Haemost. 19, 513–521 (2020). (PMID: 3323090410.1111/jth.15191)
Aid, M. et al. Vascular disease and thrombosis in SARS-CoV-2-infected rhesus macaques. Cell 183, 1354–1366 (2020). (PMID: 33065030754618110.1016/j.cell.2020.10.005)
Bazzan, M. et al. Low ADAMTS 13 plasma levels are predictors of mortality in COVID-19 patients. Intern. Emerg. Med. 15, 861–863 (2020). (PMID: 3255738310.1007/s11739-020-02394-07300200)
Zuo, Y. et al. Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19. Sci. Transl Med. 12, eabd3876 (2020). (PMID: 33139519772427310.1126/scitranslmed.abd3876)
Manne, B. K. et al. Platelet gene expression and function in COVID-19 patients. Blood 136, 1317–1329 (2020). (PMID: 3257371110.1182/blood.2020007214)
Everitt, A. R. et al. IFITM3 restricts the morbidity and mortality associated with influenza. Nature 484, 519–523 (2012). (PMID: 22446628364878610.1038/nature10921)
Zhang, Y. et al. Interferon-induced transmembrane protein 3 genetic variant rs12252-C associated with disease severity in coronavirus disease 2019. J. Infect. Dis. 222, 34–37 (2020). (PMID: 32348495719755910.1093/infdis/jiaa224)
Bernardes, J. P. et al. Longitudinal multi-omics analyses identify responses of megakaryocytes, erythroid cells, and plasmablasts as hallmarks of severe COVID-19. Immunity 53, 1296–1314 (2020). (PMID: 33296687768930610.1016/j.immuni.2020.11.017)
Campbell, R. A. et al. Human megakaryocytes possess intrinsic antiviral immunity through regulated induction of IFITM3. Blood 133, 2013–2026 (2019). (PMID: 30723081650954610.1182/blood-2018-09-873984)
Zuo, Y. et al. Neutrophil extracellular traps in COVID-19. JCI Insight 5, e138999 (2020). (PMID: 7308057)
Middleton, E. A. et al. Neutrophil extracellular traps (NETs) contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome. Blood 136, 1169–1179 (2020). (PMID: 3259795410.1182/blood.2020007008)
Rossaint, J. et al. Synchronized integrin engagement and chemokine activation is crucial in neutrophil extracellular trap-mediated sterile inflammation. Blood 123, 2573–2584 (2014). (PMID: 2433523010.1182/blood-2013-07-516484)
Yost, C. C. et al. Neonatal NET-inhibitory factor and related peptides inhibit neutrophil extracellular trap formation. J. Clin. Invest. 126, 3783–3798 (2016). (PMID: 27599294509680910.1172/JCI83873)
Veras, F. P. et al. SARS-CoV-2-triggered neutrophil extracellular traps mediate COVID-19 pathology. J. Exp. Med. 217, e20201129 (2020). (PMID: 32926098748886810.1084/jem.20201129)
Blasco, A. et al. Assessment of neutrophil extracellular traps in coronary thrombus of a case series of patients with COVID-19 and myocardial infarction. JAMA Cardiol. 6, 469–474 (2021). (PMID: 10.1001/jamacardio.2020.7308)
Hottz, E. D. et al. Platelet activation and platelet-monocyte aggregate formation trigger tissue factor expression in patients with severe COVID-19. Blood 136, 1330–1341 (2020). (PMID: 3267842810.1182/blood.2020007252)
Ramlall, V. et al. Immune complement and coagulation dysfunction in adverse outcomes of SARS-CoV-2 infection. Nat. Med. 26, 1609–1615 (2020). (PMID: 32747830780963410.1038/s41591-020-1021-2)
Magro, C. et al. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases. Transl Res. 220, 1–13 (2020). (PMID: 32299776715824810.1016/j.trsl.2020.04.007)
Skendros, P. et al. Complement and tissue factor-enriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis. J. Clin. Invest. 130, 6151–6157 (2020). (PMID: 32759504759804010.1172/JCI141374)
Gralinski, L. E. et al. Complement activation contributes to severe acute respiratory syndrome coronavirus pathogenesis. mBio 9, e01753-18 (2018). (PMID: 30301856617862110.1128/mBio.01753-18)
Jiang, Y. et al. Blockade of the C5a-C5aR axis alleviates lung damage in hDPP4-transgenic mice infected with MERS-CoV. Emerg. Microbes Infect. 7, 77 (2018). (PMID: 29691378591558010.1038/s41426-018-0063-8)
Le, V. B. et al. Platelet activation and aggregation promote lung inflammation and influenza virus pathogenesis. Am. J. Respir. Crit. Care Med. 191, 804–819 (2015). (PMID: 2566439110.1164/rccm.201406-1031OC)
Risitano, A. M. et al. Complement as a target in COVID-19? Nat. Rev. Immunol. 20, 343–344 (2020). (PMID: 3232771910.1038/s41577-020-0320-7)
Duerschmied, D. et al. Platelet serotonin promotes the recruitment of neutrophils to sites of acute inflammation in mice. Blood 121, 1008–1015 (2013). (PMID: 23243271356733510.1182/blood-2012-06-437392)
Karshovska, E., Weber, C. & von Hundelshausen, P. Platelet chemokines in health and disease. Thromb. Haemost. 110, 894–902 (2013). (PMID: 2378340110.1160/TH13-04-0341)
Palabrica, T. et al. Leukocyte accumulation promoting fibrin deposition is mediated in vivo by P-selectin on adherent platelets. Nature 359, 848–851 (1992). (PMID: 127943310.1038/359848a0)
Wang, Y. et al. Leukocyte integrin Mac-1 regulates thrombosis via interaction with platelet GPIbα. Nat. Commun. 8, 15559 (2017). (PMID: 28555620547751910.1038/ncomms15559)
Downing, L. J. et al. Anti-P-selectin antibody decreases inflammation and thrombus formation in venous thrombosis. J. Vasc. Surg. 25, 816–827 (1997). (PMID: 915230910.1016/S0741-5214(97)70211-8)
Myers, D. D. Jr. et al. Decreased venous thrombosis with an oral inhibitor of P selectin. J. Vasc. Surg. 42, 329–336 (2005). (PMID: 1610263510.1016/j.jvs.2005.04.045)
Blann, A. D., Nadar, S. K. & Lip, G. Y. The adhesion molecule P-selectin and cardiovascular disease. Eur. Heart J. 24, 2166–2179 (2003). (PMID: 1465976810.1016/j.ehj.2003.08.021)
Ridker, P. M., Buring, J. E. & Rifai, N. Soluble P-selectin and the risk of future cardiovascular events. Circulation 103, 491–495 (2001). (PMID: 1115771110.1161/01.CIR.103.4.491)
Riegger, J. et al. Histopathological evaluation of thrombus in patients presenting with stent thrombosis. A multicenter European study: a report of the prevention of late stent thrombosis by an interdisciplinary global European effort consortium. Eur. Heart J. 37, 1538–1549 (2016). (PMID: 2676195010.1093/eurheartj/ehv419)
Savchenko, A. S. et al. Neutrophil extracellular traps form predominantly during the organizing stage of human venous thromboembolism development. J. Thromb. Haemost. 12, 860–870 (2014). (PMID: 24674135405551610.1111/jth.12571)
Etulain, J. et al. P-selectin promotes neutrophil extracellular trap formation in mice. Blood 126, 242–246 (2015). (PMID: 25979951449796410.1182/blood-2015-01-624023)
Maugeri, N. et al. Activated platelets present high mobility group Box 1 to neutrophils, inducing autophagy and promoting the extrusion of neutrophil extracellular traps. J. Thromb. Haemost. 12, 2074–2088 (2014). (PMID: 2516351210.1111/jth.12710)
Stark, K. et al. Disulfide HMGB1 derived from platelets coordinates venous thrombosis in mice. Blood 128, 2435–2449 (2016). (PMID: 27574188514702310.1182/blood-2016-04-710632)
Noubouossie, D. F., Reeves, B. N., Strahl, B. D. & Key, N. S. Neutrophils: back in the thrombosis spotlight. Blood 133, 2186–2197 (2019). (PMID: 30898858721873110.1182/blood-2018-10-862243)
Noubouossie, D. F. et al. In vitro activation of coagulation by human neutrophil DNA and histone proteins but not neutrophil extracellular traps. Blood 129, 1021–1029 (2017). (PMID: 27919911532471510.1182/blood-2016-06-722298)
Pircher, J. et al. Cathelicidins prime platelets to mediate arterial thrombosis and tissue inflammation. Nat. Commun. 9, 1523 (2018). (PMID: 29670076590663610.1038/s41467-018-03925-2)
Doring, Y. et al. Lack of neutrophil-derived CRAMP reduces atherosclerosis in mice. Circ. Res. 110, 1052–1056 (2012). (PMID: 2239451910.1161/CIRCRESAHA.112.265868)
Soehnlein, O. et al. Neutrophil-derived cathelicidin protects from neointimal hyperplasia. Sci. Transl Med. 3, 103ra198 (2011). (PMID: 10.1126/scitranslmed.3002531)
Marx, C. et al. Eosinophil-platelet interactions promote atherosclerosis and stabilize thrombosis with eosinophil extracellular traps. Blood 134, 1859–1872 (2019). (PMID: 31481482690880610.1182/blood.2019000518)
Moosbauer, C. et al. Eosinophils are a major intravascular location for tissue factor storage and exposure. Blood 109, 995–1002 (2007). (PMID: 1700337910.1182/blood-2006-02-004945)
Uderhardt, S. et al. Enzymatic lipid oxidation by eosinophils propagates coagulation, hemostasis, and thrombotic disease. J. Exp. Med. 214, 2121–2138 (2017). (PMID: 28566277550242410.1084/jem.20161070)
Ames, P. R., Margaglione, M., Mackie, S. & Alves, J. D. Eosinophilia and thrombophilia in churg strauss syndrome: a clinical and pathogenetic overview. Clin. Appl. Thromb. Hemost. 16, 628–636 (2010). (PMID: 1983361810.1177/1076029609348647)
Cugno, M., Marzano, A. V., Lorini, M., Carbonelli, V. & Tedeschi, A. Enhanced tissue factor expression by blood eosinophils from patients with hypereosinophilia: a possible link with thrombosis. PLoS ONE 9, e111862 (2014). (PMID: 25375118422294410.1371/journal.pone.0111862)
Gao, S. J. et al. Hypereosinophilic syndrome presenting with multiple organ infiltration and deep venous thrombosis: a case report and literature review. Medicine 95, e4658 (2016). (PMID: 27583887500857110.1097/MD.0000000000004658)
Yousefi, S. et al. Catapult-like release of mitochondrial DNA by eosinophils contributes to antibacterial defense. Nat. Med. 14, 949–953 (2008). (PMID: 1869024410.1038/nm.1855)
Heit, J. A. et al. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch. Intern. Med. 160, 761–768 (2000). (PMID: 1073727510.1001/archinte.160.6.761)
Prandoni, P. et al. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. Haematologica 92, 199–205 (2007). (PMID: 1729656910.3324/haematol.10516)
Goldhaber, S. Z. & Bounameaux, H. Pulmonary embolism and deep vein thrombosis. Lancet 379, 1835–1846 (2012). (PMID: 2249482710.1016/S0140-6736(11)61904-1)
Nieto, J. A. et al. Fatal bleeding in patients receiving anticoagulant therapy for venous thromboembolism: findings from the RIETE registry. J. Thromb. Haemost. 8, 1216–1222 (2010). (PMID: 2034572710.1111/j.1538-7836.2010.03852.x)
Heit, J. A. Epidemiology of venous thromboembolism. Nat. Rev. Cardiol. 12, 464–474 (2015). (PMID: 26076949462429810.1038/nrcardio.2015.83)
Heit, J. A. et al. The epidemiology of venous thromboembolism in the community. Thromb. Haemost. 86, 452–463 (2001). (PMID: 1148703610.1055/s-0037-1616243)
Cohen, A. T. et al. Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb. Haemost. 98, 756–764 (2007). (PMID: 1793879810.1160/TH07-03-0212)
Chiu, J. J. & Chien, S. Effects of disturbed flow on vascular endothelium: pathophysiological basis and clinical perspectives. Physiol. Rev. 91, 327–387 (2011). (PMID: 10.1152/physrev.00047.200921248169)
Mohan, S., Mohan, N., Valente, A. J. & Sprague, E. A. Regulation of low shear flow-induced HAEC VCAM-1 expression and monocyte adhesion. Am. J. Physiol. 276, C1100–C1107 (1999). (PMID: 1032995810.1152/ajpcell.1999.276.5.C1100)
Gupta, N. et al. Activation of NLRP3 inflammasome complex potentiates venous thrombosis in response to hypoxia. Proc. Natl Acad. Sci. USA 114, 4763–4768 (2017). (PMID: 28420787542282310.1073/pnas.1620458114)
Ponomaryov, T., Payne, H., Fabritz, L., Wagner, D. D. & Brill, A. Mast cells granular contents are crucial for deep vein thrombosis in mice. Circ. Res. 121, 941–950 (2017). (PMID: 28739590562308910.1161/CIRCRESAHA.117.311185)
Subramaniam, S. et al. Distinct contributions of complement factors to platelet activation and fibrin formation in venous thrombus development. Blood 129, 2291–2302 (2017). (PMID: 28223279539948510.1182/blood-2016-11-749879)
Yago, T., Liu, Z., Ahamed, J. & McEver, R. P. Cooperative PSGL-1 and CXCR2 signaling in neutrophils promotes deep vein thrombosis in mice. Blood 132, 1426–1437 (2018). (PMID: 30068506616176910.1182/blood-2018-05-850859)
Brill, A. et al. Neutrophil extracellular traps promote deep vein thrombosis in mice. J. Thromb. Haemost. 10, 136–144 (2012). (PMID: 22044575331965110.1111/j.1538-7836.2011.04544.x)
Venereau, E., Schiraldi, M., Uguccioni, M. & Bianchi, M. E. HMGB1 and leukocyte migration during trauma and sterile inflammation. Mol. Immunol. 55, 76–82 (2013). (PMID: 2320710110.1016/j.molimm.2012.10.037)
Magder, L. S. & Petri, M. Incidence of and risk factors for adverse cardiovascular events among patients with systemic lupus erythematosus. Am. J. Epidemiol. 176, 708–719 (2012). (PMID: 23024137357125010.1093/aje/kws130)
Leffler, J. et al. Neutrophil extracellular traps that are not degraded in systemic lupus erythematosus activate complement exacerbating the disease. J. Immunol. 188, 3522–3531 (2012). (PMID: 2234566610.4049/jimmunol.1102404)
Lood, C. et al. Increased C1q, C4 and C3 deposition on platelets in patients with systemic lupus erythematosus–a possible link to venous thrombosis? Lupus 21, 1423–1432 (2012). (PMID: 2287825610.1177/0961203312457210)
Espinosa, G. & Cervera, R. Antiphospholipid syndrome: frequency, main causes and risk factors of mortality. Nat. Rev. Rheumatol. 6, 296–300 (2010). (PMID: 2038656310.1038/nrrheum.2010.47)
Fischetti, F. et al. Thrombus formation induced by antibodies to β2-glycoprotein I is complement dependent and requires a priming factor. Blood 106, 2340–2346 (2005). (PMID: 1595628810.1182/blood-2005-03-1319)
Girardi, G. et al. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J. Clin. Invest. 112, 1644–1654 (2003). (PMID: 1466074128164310.1172/JCI200318817)
Girardi, G., Redecha, P. & Salmon, J. E. Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat. Med. 10, 1222–1226 (2004). (PMID: 1548985810.1038/nm1121)
Garcia-Romo, G. S. et al. Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus. Sci. Transl Med. 3, 73ra20 (2011). (PMID: 21389264314383710.1126/scitranslmed.3001201)
Solomon, D. H. et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 107, 1303–1307 (2003). (PMID: 1262895210.1161/01.CIR.0000054612.26458.B2)
Hannawi, S., Haluska, B., Marwick, T. H. & Thomas, R. Atherosclerotic disease is increased in recent-onset rheumatoid arthritis: a critical role for inflammation. Arthritis Res. Ther. 9, R116 (2007). (PMID: 17986352224623410.1186/ar2323)
Maradit-Kremers, H. et al. Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum. 52, 402–411 (2005). (PMID: 1569301010.1002/art.20853)
Khandpur, R. et al. NETs are a source of citrullinated autoantigens and stimulate inflammatory responses in rheumatoid arthritis. Sci. Transl Med. 5, 178ra140 (2013). (PMID: 10.1126/scitranslmed.3005580)
Massberg, S. et al. A critical role of platelet adhesion in the initiation of atherosclerotic lesion formation. J. Exp. Med. 196, 887–896 (2002). (PMID: 12370251219402510.1084/jem.20012044)
Massberg, S. et al. Platelet adhesion via glycoprotein IIb integrin is critical for atheroprogression and focal cerebral ischemia: an in vivo study in mice lacking glycoprotein IIb. Circulation 112, 1180–1188 (2005). (PMID: 1610323510.1161/CIRCULATIONAHA.105.539221)
Gerdes, N. et al. Platelet CD40 exacerbates atherosclerosis by transcellular activation of endothelial cells and leukocytes. Arterioscler. Thromb. Vasc. Biol. 36, 482–490 (2016). (PMID: 2682195010.1161/ATVBAHA.115.307074)
Drechsler, M., Megens, R. T., van Zandvoort, M., Weber, C. & Soehnlein, O. Hyperlipidemia-triggered neutrophilia promotes early atherosclerosis. Circulation 122, 1837–1845 (2010). (PMID: 2095620710.1161/CIRCULATIONAHA.110.961714)
Koenen, R. R. et al. Disrupting functional interactions between platelet chemokines inhibits atherosclerosis in hyperlipidemic mice. Nat. Med. 15, 97–103 (2009). (PMID: 1912265710.1038/nm.1898)
Massberg, S. et al. Platelets secrete stromal cell-derived factor 1α and recruit bone marrow-derived progenitor cells to arterial thrombi in vivo. J. Exp. Med. 203, 1221–1233 (2006). (PMID: 16618794212120510.1084/jem.20051772)
Silvestre-Roig, C. et al. Externalized histone H4 orchestrates chronic inflammation by inducing lytic cell death. Nature 569, 236–240 (2019). (PMID: 31043745671652510.1038/s41586-019-1167-6)
Xia, G. L., Wang, Y. K. & Huang, Z. Q. The correlation of serum myeloid-related protein-8/14 and eosinophil cationic protein in patients with coronary artery disease. BioMed. Res. Int. 2016, 4980251 (2016). (PMID: 27022611478906110.1155/2016/4980251)
Niccoli, G. et al. Eosinophil cationic protein: a new biomarker of coronary atherosclerosis. Atherosclerosis 211, 606–611 (2010). (PMID: 2030788310.1016/j.atherosclerosis.2010.02.038)
Haley, K. J. et al. Overexpression of eotaxin and the CCR3 receptor in human atherosclerosis: using genomic technology to identify a potential novel pathway of vascular inflammation. Circulation 102, 2185–2189 (2000). (PMID: 1105609010.1161/01.CIR.102.18.2185)
Pertiwi, K. R. et al. Extracellular traps derived from macrophages, mast cells, eosinophils and neutrophils are generated in a time-dependent manner during atherothrombosis. J. Pathol. 247, 505–512 (2018). (PMID: 10.1002/path.5212)
van Dijk, R. A. et al. Systematic evaluation of the cellular innate immune response during the process of human atherosclerosis. J. Am. Heart Assoc. 5, e002860 (2016). (PMID: 27312803493725010.1161/JAHA.115.002860)
Novotny, J. et al. Thrombus NET content is associated with clinical outcome in stroke and myocardial infarction. Neurology 94, e2346–e2360 (2020). (PMID: 3243486510.1212/WNL.0000000000009532)
Gudbjartsson, D. F. et al. Sequence variants affecting eosinophil numbers associate with asthma and myocardial infarction. Nat. Genet. 41, 342–347 (2009). (PMID: 1919861010.1038/ng.323)
Pircher, J., Engelmann, B., Massberg, S. & Schulz, C. Platelet-neutrophil crosstalk in atherothrombosis. Thromb. Haemost. 119, 1274–1282 (2019). (PMID: 3125497510.1055/s-0039-1692983)
Tardif, J. C. et al. Effects of the P-selectin antagonist inclacumab on myocardial damage after percutaneous coronary intervention for non-ST-segment elevation myocardial infarction: results of the SELECT-ACS trial. J. Am. Coll. Cardiol. 61, 2048–2055 (2013). (PMID: 2350023010.1016/j.jacc.2013.03.003)
Dhanesha, N. et al. Targeting myeloid-cell specific integrin α9β1 inhibits arterial thrombosis in mice. Blood 135, 857–861 (2020). (PMID: 31951649706803310.1182/blood.2019002846)
Faraday, N. et al. Cathepsin G-dependent modulation of platelet thrombus formation in vivo by blood neutrophils. PLoS ONE 8, e71447 (2013). (PMID: 23940756373395810.1371/journal.pone.0071447)
Ortega-Gomez, A. et al. Cathepsin G controls arterial but not venular myeloid cell recruitment. Circulation 134, 1176–1188 (2016). (PMID: 27660294528800710.1161/CIRCULATIONAHA.116.024790)
Vogel, S. et al. Platelet-derived HMGB1 is a critical mediator of thrombosis. J. Clin. Invest. 125, 4638–4654 (2015). (PMID: 26551681466578510.1172/JCI81660)
Franck, G. et al. Roles of PAD4 and NETosis in experimental atherosclerosis and arterial injury: implications for superficial erosion. Circ. Res. 123, 33–42 (2018). (PMID: 29572206601487210.1161/CIRCRESAHA.117.312494)
Liu, Y. et al. Myeloid-specific deletion of peptidylarginine deiminase 4 mitigates atherosclerosis. Front. Immunol. 9, 1680 (2018). (PMID: 30140264609496610.3389/fimmu.2018.01680)
Novotny, J. et al. Histological comparison of arterial thrombi in mice and men and the influence of Cl-amidine on thrombus formation. PLoS ONE 13, e0190728 (2018). (PMID: 29293656574986210.1371/journal.pone.0190728)
Schreiber, A. et al. Necroptosis controls NET generation and mediates complement activation, endothelial damage, and autoimmune vasculitis. Proc. Natl Acad. Sci. USA 114, E9618–E9625 (2017). (PMID: 29078325569255410.1073/pnas.1708247114)
Wang, H., Wang, C., Zhao, M. H. & Chen, M. Neutrophil extracellular traps can activate alternative complement pathways. Clin. Exp. Immunol. 181, 518–527 (2015). (PMID: 25963026455738710.1111/cei.12654)
Gushiken, F. C., Han, H., Li, J., Rumbaut, R. E. & Afshar-Kharghan, V. Abnormal platelet function in C3-deficient mice. J. Thromb. Haemost. 7, 865–870 (2009). (PMID: 19291167286767310.1111/j.1538-7836.2009.03334.x)
Sauter, R. J. et al. Functional relevance of the anaphylatoxin receptor C3aR for platelet function and arterial thrombus formation marks an intersection point between innate immunity and thrombosis. Circulation 138, 1720–1735 (2018). (PMID: 29802205620224410.1161/CIRCULATIONAHA.118.034600)
Jaiswal, S. et al. Age-related clonal hematopoiesis associated with adverse outcomes. N. Engl. J. Med. 371, 2488–2498 (2014). (PMID: 25426837430666910.1056/NEJMoa1408617)
Jaiswal, S. et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N. Engl. J. Med. 377, 111–121 (2017). (PMID: 28636844671750910.1056/NEJMoa1701719)
Fuster, J. J. et al. Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice. Science 355, 842–847 (2017). (PMID: 28104796554205710.1126/science.aag1381)
James, C. et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434, 1144–1148 (2005). (PMID: 1579356110.1038/nature03546)
Wolach, O. et al. Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms. Sci. Transl Med. 10, eaan8292 (2018). (PMID: 29643232644246610.1126/scitranslmed.aan8292)
Wang, W. et al. Macrophage inflammation, erythrophagocytosis, and accelerated atherosclerosis in Jak2 (V617F) Mice. Circ. Res. 123, e35–e47 (2018). (PMID: 30571460630979610.1161/CIRCRESAHA.118.313283)
Cull, A. H., Snetsinger, B., Buckstein, R., Wells, R. A. & Rauh, M. J. Tet2 restrains inflammatory gene expression in macrophages. Exp. Hematol. 55, 56–70 (2017). (PMID: 2882685910.1016/j.exphem.2017.08.001)
Zhang, Q. et al. Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6. Nature 525, 389–393 (2015). (PMID: 26287468469774710.1038/nature15252)
Veninga, A., De Simone, I., Heemskerk, J. W. M., Cate, H. T. & van der Meijden, P. E. J. Clonal hematopoietic mutations linked to platelet traits and the risk of thrombosis or bleeding. Haematologica 105, 2020–2031 (2020). (PMID: 32554558739529010.3324/haematol.2019.235994)
Bonaca, M. P. et al. Rivaroxaban in peripheral artery disease after revascularization. N. Engl. J. Med. 382, 1994–2004 (2020). (PMID: 3222213510.1056/NEJMoa2000052)
Borissoff, J. I., Spronk, H. M. & ten Cate, H. The hemostatic system as a modulator of atherosclerosis. N. Engl. J. Med. 364, 1746–1760 (2011). (PMID: 2154274510.1056/NEJMra1011670)
Eikelboom, J. W. et al. Rivaroxaban with or without aspirin in stable cardiovascular disease. N. Engl. J. Med. 377, 1319–1330 (2017). (PMID: 2884419210.1056/NEJMoa1709118)
Gadi, I. et al. Different DOACs control inflammation in cardiac ischemia-reperfusion differently. Circ. Res. 128, 513–529 (2020). (PMID: 3335337310.1161/CIRCRESAHA.120.3172198293866)
Hara, T. et al. Rivaroxaban, a novel oral anticoagulant, attenuates atherosclerotic plaque progression and destabilization in ApoE-deficient mice. Atherosclerosis 242, 639–646 (2015). (PMID: 2581732910.1016/j.atherosclerosis.2015.03.023)
Vu, T. K., Hung, D. T., Wheaton, V. I. & Coughlin, S. R. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 64, 1057–1068 (1991). (PMID: 167226510.1016/0092-8674(91)90261-V)
Nidorf, S. M. et al. Colchicine in patients with chronic coronary disease. N. Engl. J. Med. 383, 1838–1847 (2020). (PMID: 3286538010.1056/NEJMoa2021372)
Ridker, P. M. et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N. Engl. J. Med. 377, 1119–1131 (2017). (PMID: 2884575110.1056/NEJMoa1707914)
Tardif, J. C. et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N. Engl. J. Med. 381, 2497–2505 (2019). (PMID: 3173314010.1056/NEJMoa1912388)
Kirchhof, P. et al. Effects of rivaroxaban on biomarkers of coagulation and inflammation: a post hoc analysis of the X-VeRT TRIAL. TH Open 4, e20–e32 (2020). (PMID: 31984306697817710.1055/s-0040-1701206)
Busch, G. et al. Coagulation factor Xa stimulates interleukin-8 release in endothelial cells and mononuclear leukocytes: implications in acute myocardial infarction. Arterioscler. Thromb. Vasc. Biol. 25, 461–466 (2005). (PMID: 1555069610.1161/01.ATV.0000151279.35780.2d)
Daubie, V. et al. Factor Xa and thrombin evoke additive calcium and proinflammatory responses in endothelial cells subjected to coagulation. Biochim. Biophys. Acta 1763, 860–869 (2006). (PMID: 1676546610.1016/j.bbamcr.2006.04.010)
Senden, N. H. et al. Factor Xa induces cytokine production and expression of adhesion molecules by human umbilical vein endothelial cells. J. Immunol. 161, 4318–4324 (1998). (PMID: 978020810.4049/jimmunol.161.8.4318)
Ichikawa, H. et al. Rivaroxaban, a direct factor Xa inhibitor, ameliorates hypertensive renal damage through inhibition of the inflammatory response mediated by protease-activated receptor pathway. J. Am. Heart Assoc. 8, e012195 (2019). (PMID: 30957622650718710.1161/JAHA.119.012195)
Wildhagen, K. C. et al. Nonanticoagulant heparin prevents histone-mediated cytotoxicity in vitro and improves survival in sepsis. Blood 123, 1098–1101 (2014). (PMID: 2426423110.1182/blood-2013-07-514984)
Mansour, A., Bachelot-Loza, C., Nesseler, N., Gaussem, P. & Gouin-Thibault, I. P2Y12 inhibition beyond thrombosis: effects on inflammation. Int. J. Mol. Sci. 21, 1391 (2020). (PMID: 707304010.3390/ijms21041391)
Mackman, N., Bergmeier, W., Stouffer, G. A. & Weitz, J. I. Therapeutic strategies for thrombosis: new targets and approaches. Nat. Rev. Drug Discov. 19, 333–352 (2020). (PMID: 3213267810.1038/s41573-020-0061-0)
Jeong, H. S. et al. Comparison of ticagrelor versus prasugrel for inflammation, vascular function, and circulating endothelial progenitor cells in diabetic patients with non-ST-segment elevation acute coronary syndrome requiring coronary stenting: a prospective, randomized, crossover trial. JACC Cardiovasc. Interv. 10, 1646–1658 (2017). (PMID: 2883847510.1016/j.jcin.2017.05.064)
Morris, T. et al. Effects of low-dose aspirin on acute inflammatory responses in humans. J. Immunol. 183, 2089–2096 (2009). (PMID: 1959700210.4049/jimmunol.0900477)
Paul-Clark, M. J., Van Cao, T., Moradi-Bidhendi, N., Cooper, D. & Gilroy, D. W. 15-epi-lipoxin A4-mediated induction of nitric oxide explains how aspirin inhibits acute inflammation. J. Exp. Med. 200, 69–78 (2004). (PMID: 15238606221331110.1084/jem.20040566)
Dutta, P. et al. Myocardial infarction accelerates atherosclerosis. Nature 487, 325–329 (2012). (PMID: 22763456340132610.1038/nature11260)
Sager, H. B. et al. Targeting interleukin-1β reduces leukocyte production after acute myocardial infarction. Circulation 132, 1880–1890 (2015). (PMID: 26358260465179510.1161/CIRCULATIONAHA.115.016160)
Gomez, D. et al. Interleukin-1β has atheroprotective effects in advanced atherosclerotic lesions of mice. Nat. Med. 24, 1418–1429 (2018). (PMID: 30038218613082210.1038/s41591-018-0124-5)
Alexander, M. R. et al. Genetic inactivation of IL-1 signaling enhances atherosclerotic plaque instability and reduces outward vessel remodeling in advanced atherosclerosis in mice. J. Clin. Invest. 122, 70–79 (2012). (PMID: 2220168110.1172/JCI43713)
Ridker, P. M. et al. Low-dose methotrexate for the prevention of atherosclerotic events. N. Engl. J. Med. 380, 752–762 (2019). (PMID: 3041561010.1056/NEJMoa1809798)
Munoz, L. E. et al. Neutrophil extracellular traps initiate gallstone formation. Immunity 51, 443–450 (2019). (PMID: 3142287010.1016/j.immuni.2019.07.002)
Martinon, F., Petrilli, V., Mayor, A., Tardivel, A. & Tschopp, J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440, 237–241 (2006). (PMID: 1640788910.1038/nature04516)
Opstal, T. S. J. et al. Colchicine attenuates inflammation beyond the inflammasome in chronic coronary artery disease: a LoDoCo2 proteomic substudy. Circulation 142, 1996–1998 (2020). (PMID: 3286499810.1161/CIRCULATIONAHA.120.050560)
Castro, M. et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir. Med. 3, 355–366 (2015). (PMID: 2573699010.1016/S2213-2600(15)00042-9)
FitzGerald, J. M. et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 388, 2128–2141 (2016). (PMID: 2760940610.1016/S0140-6736(16)31322-8)
Ortega, H. G. et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N. Engl. J. Med. 371, 1198–1207 (2014). (PMID: 2519905910.1056/NEJMoa1403290)
Mastellos, D. C., Ricklin, D. & Lambris, J. D. Clinical promise of next-generation complement therapeutics. Nat. Rev. Drug Discov. 18, 707–729 (2019). (PMID: 31324874734085310.1038/s41573-019-0031-6)
Liverani, E., Rico, M. C., Tsygankov, A. Y., Kilpatrick, L. E. & Kunapuli, S. P. P2Y12 receptor modulates sepsis-induced inflammation. Arterioscler. Thromb. Vasc. Biol. 36, 961–971 (2016). (PMID: 27055904485011310.1161/ATVBAHA.116.307401)
Sexton, T. R. et al. Ticagrelor reduces thromboinflammatory markers in patients with pneumonia. JACC Basic Transl. Sci. 3, 435–449 (2018). (PMID: 30175268611570310.1016/j.jacbts.2018.05.005)
Hillmen, P. et al. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood 110, 4123–4128 (2007). (PMID: 1770289710.1182/blood-2007-06-095646)
Dong, Y. et al. TLR4 regulates ROS and autophagy to control neutrophil extracellular traps formation against Streptococcus pneumoniae in acute otitis media. Pediatr. Res. https://doi.org/10.1038/s41390-020-0964-9 (2020). (PMID: 10.1038/s41390-020-0964-9327267997855434)
Guglietta, S. et al. Coagulation induced by C3aR-dependent NETosis drives protumorigenic neutrophils during small intestinal tumorigenesis. Nat. Commun. 7, 11037 (2016). (PMID: 26996437480216910.1038/ncomms11037)
Metzler, K. D., Goosmann, C., Lubojemska, A., Zychlinsky, A. & Papayannopoulos, V. A myeloperoxidase-containing complex regulates neutrophil elastase release and actin dynamics during NETosis. Cell Rep. 8, 883–896 (2014). (PMID: 25066128447168010.1016/j.celrep.2014.06.044)
Papayannopoulos, V., Metzler, K. D., Hakkim, A. & Zychlinsky, A. Neutrophil elastase and myeloperoxidase regulate the formation of neutrophil extracellular traps. J. Cell Biol. 191, 677–691 (2010). (PMID: 20974816300330910.1083/jcb.201006052)
Vu, T. T. et al. Histidine-rich glycoprotein binds DNA and RNA and attenuates their capacity to activate the intrinsic coagulation pathway. Thromb. Haemost. 115, 89–98 (2016). (PMID: 2635485710.1160/TH15-04-0336)
Fu, H. et al. Flow-induced elongation of von willebrand factor precedes tension-dependent activation. Nat. Commun. 8, 324 (2017). (PMID: 28831047556734310.1038/s41467-017-00230-2)
Jiang, Y., Fu, H., Springer, T. A. & Wong, W. P. Electrostatic steering enables flow-activated von willebrand factor to bind platelet glycoprotein, revealed by single-molecule stretching and imaging. J. Mol. Biol. 431, 1380–1396 (2019). (PMID: 30797858693611010.1016/j.jmb.2019.02.014)
Chonn, A., Cullis, P. R. & Devine, D. V. The role of surface charge in the activation of the classical and alternative pathways of complement by liposomes. J. Immunol. 146, 4234–4241 (1991). (PMID: 204079810.4049/jimmunol.146.12.4234) - Substance Nomenclature:
-
0 (Anti-Inflammatory Agents)
0 (Fibrinolytic Agents)
0 (Inflammation Mediators) - Entry Date(s):
- Date Created: 20210507 Date Completed: 20210825 Latest Revision: 20230201
- Update Code:
- 20240104
- PubMed Central ID:
- PMC8100938
- DOI:
- 10.1038/s41569-021-00552-1
- PMID:
- 33958774
- Czasopismo naukowe
Menu główne
Wyszukiwarka
Treść główna
